Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096239
Filing Date
2024-08-13
Accepted
2024-08-13 16:15:23
Documents
71
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q elvn-20240630.htm   iXBRL 10-Q 2571672
2 EX-3.1 elvn-ex3_1.htm EX-3.1 115616
3 EX-31.1 elvn-ex31_1.htm EX-31.1 14677
4 EX-31.2 elvn-ex31_2.htm EX-31.2 14662
5 EX-32.1 elvn-ex32_1.htm EX-32.1 8968
6 EX-32.2 elvn-ex32_2.htm EX-32.2 8958
7 GRAPHIC img252670033_0.jpg GRAPHIC 78578
  Complete submission text file 0000950170-24-096239.txt   8910872

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20240630.xsd EX-101.SCH 1191989
74 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20240630_htm.xml XML 1263071
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39247 | Film No.: 241201666
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)